Johnson & Johnson (NYSE:JNJ) Shares Purchased by Sterling Investment Advisors Ltd.

Sterling Investment Advisors Ltd. increased its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 2.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 58,608 shares of the company’s stock after buying an additional 1,620 shares during the period. Johnson & Johnson accounts for 2.9% of Sterling Investment Advisors Ltd.’s holdings, making the stock its 3rd largest position. Sterling Investment Advisors Ltd.’s holdings in Johnson & Johnson were worth $10,387,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Magnolia Capital Management Ltd. grew its stake in shares of Johnson & Johnson by 0.5% in the first quarter. Magnolia Capital Management Ltd. now owns 11,162 shares of the company’s stock worth $1,978,000 after purchasing an additional 55 shares during the last quarter. Howard Financial Services LTD. grew its stake in shares of Johnson & Johnson by 2.1% in the first quarter. Howard Financial Services LTD. now owns 2,757 shares of the company’s stock worth $489,000 after purchasing an additional 57 shares during the last quarter. American Financial Advisors LLC grew its stake in shares of Johnson & Johnson by 2.1% in the first quarter. American Financial Advisors LLC now owns 2,715 shares of the company’s stock worth $481,000 after purchasing an additional 57 shares during the last quarter. Capital Investment Counsel Inc grew its stake in shares of Johnson & Johnson by 0.8% in the fourth quarter. Capital Investment Counsel Inc now owns 7,796 shares of the company’s stock worth $1,334,000 after purchasing an additional 59 shares during the last quarter. Finally, Kwmg LLC grew its stake in shares of Johnson & Johnson by 2.6% in the first quarter. Kwmg LLC now owns 2,354 shares of the company’s stock worth $417,000 after purchasing an additional 59 shares during the last quarter. 68.78% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Trading Down 0.3 %

NYSE JNJ opened at $173.91 on Tuesday. The company has a market cap of $457.63 billion, a price-to-earnings ratio of 25.31, a P/E/G ratio of 3.32 and a beta of 0.59. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The business has a 50 day moving average price of $175.84 and a 200-day moving average price of $174.50. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $0.02. The company had revenue of $24.02 billion for the quarter, compared to analysts’ expectations of $23.85 billion. Johnson & Johnson had a return on equity of 36.56% and a net margin of 19.21%. Johnson & Johnson’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.48 earnings per share. As a group, equities analysts expect that Johnson & Johnson will post 10.05 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be given a dividend of $1.13 per share. The ex-dividend date is Monday, August 22nd. This represents a $4.52 annualized dividend and a dividend yield of 2.60%. Johnson & Johnson’s payout ratio is 65.79%.

Insider Activity at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,336,803. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,336,803. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at approximately $2,785,140. The disclosure for this sale can be found here. 0.35% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent analyst reports. Daiwa Capital Markets initiated coverage on shares of Johnson & Johnson in a report on Wednesday, June 22nd. They issued an “outperform” rating on the stock. The Goldman Sachs Group boosted their target price on shares of Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a report on Tuesday, April 12th. SVB Leerink dropped their target price on shares of Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a report on Friday, July 8th. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $189.89.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.